J
James Dale
Researcher at University of Glasgow
Publications - 14
Citations - 442
James Dale is an academic researcher from University of Glasgow. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 9, co-authored 14 publications receiving 380 citations. Previous affiliations of James Dale include Wishaw General Hospital & NHS Greater Glasgow and Clyde.
Papers
More filters
Journal ArticleDOI
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial
James Dale,Anne Stirling,Ruiqi Zhang,David Purves,Jonathan Foley,Martin Sambrook,Philip G. Conaghan,Désirée van der Heijde,Alex McConnachie,Iain B. McInnes,Duncan Porter +10 more
TL;DR: In early RA, a MSUS-driven T2T strategy led to more intensive treatment, but was not associated with significantly better clinical or imaging outcomes than a DAS28-driven strategy.
Journal ArticleDOI
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Duncan Porter,Jurgen van Melckebeke,James Dale,C. Martina Messow,Alex McConnachie,Andrew Walker,Robin Munro,John McLaren,Euan McRorie,Jon Packham,Christopher D. Buckley,John Harvie,Peter C. Taylor,Ernest Choy,Costantino Pitzalis,Iain B. McInnes +15 more
TL;DR: Initial treatment with rituximab is non-inferior to initial TNF inhibitor treatment in patients seropositive for rheumatoid arthritis and naive to treatment with biologicals, and is cost saving over 12 months.
Journal ArticleDOI
Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy.
TL;DR: To determine the level of agreement and potential impact on disease‐modifying antirheumatic drug (DMARD) escalation decisions and of adding musculoskeletal ultrasound (MSUS) assessment of disease activity to the Disease Activity Score in 28 joints (DAS28) in early rheumatoid arthritis (RA).
Journal ArticleDOI
Brief Report: Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort.
Caroline Kronisch,David J. McLernon,James Dale,Caron Paterson,Stuart H. Ralston,David M. Reid,Ann Tierney,John Harvie,Neil McKay,Hilary Wilson,Robin Munro,Sarah Saunders,Ruth Richmond,Derek Baxter,Mike McMahon,Vinod Kumar,John McLaren,Stefan Siebert,Iain B. McInnes,Duncan Porter,Gary J. Macfarlane,Neil Basu +21 more
TL;DR: The Scottish Early Rheumatoid Arthritis (SERA) inception cohort is a multicenter, prospective study of patients with newly presenting RA or undifferentiated arthritis.
Journal ArticleDOI
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation.
Rónán Daly,Gavin Blackburn,Cameron Best,Carl S. Goodyear,Manikhandan Mudaliar,Karl Burgess,Karl Burgess,Anne Stirling,Duncan Porter,Duncan Porter,Iain B. McInnes,Michael P. Barrett,James Dale,James Dale +13 more
TL;DR: Quantitative metabolic biomarker-based tests of clinical change in state are feasible and should be developed around the itaconate pathway, and reveal for the first time a link between itaconates production and resolution of inflammatory disease in humans.